Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis

Show full item record



Permalink

http://hdl.handle.net/10138/233837

Citation

Arpalahti , L , Laitinen , A , Hagström , J , Mustonen , H , Kokkola , A , Böckelman , C , Haglund , C & Holmberg , C I 2018 , ' Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis ' , PLoS One , vol. 13 , no. 2 , 0193125 . https://doi.org/10.1371/journal.pone.0193125

Title: Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis
Author: Arpalahti, Leena; Laitinen, Alli; Hagström, Jaana; Mustonen, Harri; Kokkola, Arto; Böckelman, Camilla; Haglund, Caj; Holmberg, Carina I.
Other contributor: University of Helsinki, Translational Cancer Biology (TCB) Research Programme
University of Helsinki, Medicum
University of Helsinki, Clinicum
University of Helsinki, II kirurgian klinikka
University of Helsinki, Research Programs Unit
University of Helsinki, Translational Cancer Biology (TCB) Research Programme
University of Helsinki, Research Programs Unit










Date: 2018-02-23
Language: eng
Number of pages: 11
Belongs to series: PLoS One
ISSN: 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0193125
URI: http://hdl.handle.net/10138/233837
Abstract: Gastric cancer is the second most common cause of cancer-related mortality worldwide. Accurate prediction of disease progression is difficult, and new biomarkers for clinical use are essential. Recently, we reported that the proteasome-associated deubiquitinating enzyme UCHL5/Uch37 is a new prognostic marker in both rectal cancer and pancreatic ductal adenocarcinoma. Here, we have assessed by immunohistochemistry UCHL5 tumor expression in gastric cancer. The study cohort comprised 650 patients, who underwent surgery in Helsinki University Hospital, Finland, between 1983 and 2009. We investigated the association of cytoplasmic UCHL5 tumor expression to assess clinicopathological parameters and patient survival. Positive cytoplasmic UCHL5 tumor immunoexpression is linked to increased survival of patients with small (
Subject: UBIQUITIN-PROTEASOME SYSTEM
MULTIPLE-MYELOMA
INHIBITION
BORTEZOMIB
RESISTANCE
ACTIVATION
APOPTOSIS
STRATEGY
UCH37
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
file.pdf 4.738Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record